NCT03837574 French National Registry of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator
| NCT ID | NCT03837574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Paris Sudden Death Expertise Center |
| Condition | Tetralogy of Fallot |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2010-12-01 |
| Primary Completion | 2019-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2010-12-01 with a primary completion date of 2019-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
National french registry of patients with tetralogy of Fallot and implantable cardioverter defibrillator.
Eligibility Criteria
Inclusion Criteria: * tetralogy of Fallot * implantable cardioverter defibrillator Exclusion Criteria: * age \< 18 years
Contact & Investigator
Victor Waldmann, MD
PRINCIPAL INVESTIGATOR
Paris Sudden Death Expertise Center
Frequently Asked Questions
Who can join the NCT03837574 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tetralogy of Fallot. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03837574 currently recruiting?
Yes, NCT03837574 is actively recruiting participants. Contact the research team at vicrtor.waldmann@inserm.fr for enrollment information.
Where is the NCT03837574 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT03837574 clinical trial?
NCT03837574 is sponsored by Paris Sudden Death Expertise Center. The principal investigator is Victor Waldmann, MD at Paris Sudden Death Expertise Center. The trial plans to enroll 150 participants.